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Abstract 
Aims. The ‘obesity paradox’ is consistently observed in patients with heart failure (HF). We investigated the 
relationship of body surface area (BSA) to mortality and hospitalizations in patients with chronic HF. 
Methods and results. Data from the outpatient cohort of the observational, prospective, Heart Failure Long‐Term 
Registry of the Heart Failure Association of the European Society of Cardiology was analysed in order to evaluate the 
prognostic significance of BSA in chronic HF. A total of 9104 chronic HF patients (age 64.8 ± 13.4 years; 71.6% 
males) were enrolled. Mortality during 1‐year follow‐up was observed in 718 of 8875 (8.1%) patients. A progressive, 
inverse relationship between all‐cause mortality and BSA levels was observed; the adjusted hazard ratio (HR) for 1‐
year mortality was 1.823 [95% confidence interval (CI) 1.398–2.376], P < 0.001 for the lowest quartile of BSA <1.78 
m2, and 1.255, 95% CI 1.000–1.576, P = 0.05 for the middle two quartiles (1.78 ≤BSA ≤2.07 m2), compared with the 
highest quartile (BSA >2.07 m2). For each increase of 0.1 m2 in BSA, an adjusted HR of 0.908 (95% CI 0.870–
0.948), P < 0.001 for mortality was calculated. HF hospitalizations were not associated with BSA subgroup 
distribution. In both genders, subjects within the lowest BSA quartile (males <1.84 m2 and females <1.64 m2) had 
significantly higher mortality rates during follow‐up (log‐rank P < 0.0001). However, the stepwise association with 
mortality was more distinct in males.  
Conclusions. Total and cardiovascular mortality, but not HF hospitalizations was inversely associated with BSA 
levels in chronic HF patients. BSA may serve as a prognostic indicator for adverse outcome in HF patients. 
Keywords 
Heart failure; Body surface area; Obesity; Prognosis  
Introduction 
Obesity is an established risk factor for the development of cardiovascular diseases including heart 
failure (HF).
1 
However, numerous studies have demonstrated survival benefit of overweight and mildly 
obese HF subjects compared with leaner individuals with HF, and the unfavourable prognostic 
significance of loss of body weight.
2-11
 This phenomenon of reverse epidemiology was termed the 
‘obesity paradox’, and is now well documented in chronic HF.  
 
Mechanisms explaining the obesity paradox in HF are not clearly defined, and include the effects of 
cardiac cachexia, catabolic state, and muscle wasting in lean HF subjects, in contrast to greater metabolic 
reserve and increased muscle mass and strength in overweight and obese HF individuals.
12, 13
 It may also 
be that obese patients present earlier in their disease course due to greater functional impairment and are 
therefore treated earlier. Furthermore, it is possible that confounding factors such as disease severity, 
lower incidence of smoking, and younger age may account for the inverse relationship between obesity 
and mortality seen in HF cohorts.
14, 15
 Nevertheless, it is still debated whether there is an intrinsic 
association between obesity and mortality in HF subjects, or whether the obesity paradox is confounded 
by other uncontrolled factors contributing to its existence.
16-18 
 
Body mass index (BMI) is the most common anthropometric parameter used in studies assessing 
obesity in patients with chronic HF, due to its widespread acceptance and ease of use. Less commonly, 
measures of body composition such as increased waist circumference and estimates of body fat were also 
shown to be associated with improved outcomes in HF.
19, 20
 Though commonly used, BMI may not be a 
reliable method to assess the distribution and degree of adiposity or a good way to correct weight for 
height. Body surface area (BSA), a method for describing body size, is commonly used as a biometric 
unit to adjust mass and volume and for indexing physiological parameters associated with cardiovascular 
disease, and may correlate more closely with prognosis in HF.
21
 Although BSA is commonly used as a 
way to ‘index’ haemodynamic parameters, its prognostic significance in HF has not been robustly 
studied.  
 
The objective of the current study was to examine the prognostic significance of BSA in predicting 
survival and hospitalizations in a large population of chronic HF patients. 
Methods 
Study design 
The chronic HF cohort of the Heart Failure Long‐Term Registry comprised the study population.22 
This registry is a prospective, multicentre, observational study of patients presenting to 211 Cardiology 
centres of 21 European and Mediterranean countries. Patients were enrolled in the registry from 
outpatient HF clinics as well as from hospital admissions for acute, pre‐existing, or new‐onset HF during 
the enrolment period, on a ‘one day per week’ basis for 12 consecutive months in each participating 
country.  
 
Included in the present study were all recruited outpatients with chronic HF diagnosed according to 
the clinical judgement of the responsible cardiologist at the participating centres. The cohort of inpatients 
admitted to hospitals for acute HF was not part of the present analysis. There were no specific exclusion 
criteria, with the exception that all patients had to be aged over 18 years. The survey was approved by 
each local Institutional Review Board according to the rules of each participating country. No data were 
collected before detailed information was provided to the patient, and a signed, informed consent was 
obtained. 
  
Baseline demographics, clinical characteristics, and co‐morbidities were recorded in all patients, 
including drug treatment and laboratory blood tests at study entry. One‐year outcome data were collected 
in each participating site, including overall and cardiovascular mortality, as well as HF hospitalizations 
during the follow‐up period. 
 
All subjects had documented BSA measurements carried out at their initial visit to the outpatient HF 
clinic. BSA was calculated according to the Mosteller formula [weight (kg) × height (cm)/3600]
1/2
.
23
 
Mosteller's formula is recommended as an accurate measure to estimate BSA, and is commonly used due 
to its simplicity and applicability in both clinical and laboratory medicine.
24
 
Statistical analysis 
Univariate analysis was applied to both continuous and categorical variables. Continuous variables 
were reported as mean ± SD or as median and interquartile range (IQR). Among‐group comparisons were 
made using a non‐parametric test (Kruskal–Wallis test). Categorical variables were reported as 
percentages. Intergroup comparisons were made using a χ2 test or a Fisher's exact test if any expected cell 
count was less than five. In order to assess the prognostic value of BSA, the patients were categorized 
into three groups based on quartiles of BSA [<Q1 (1.78 m
2
); Q1–Q3 (1.78–2.07 m2); >Q3 (2.07 m2)]. 
Additional analysis was performed for BSA as a continuous variable.  
 
Multivariable analysis was performed using the Cox proportional hazards analysis. All variables 
significant in a univariate analysis were inserted in the model. A stepwise regression model was 
performed, where BSA was the fixed variable. Hazard ratios (HRs) for overall 1‐year mortality were 
calculated for the subgroups of BSA and additional significant covariables, with 95% confidence intervals 
(CIs). Adjustment for age and gender was also performed in a separate model in order to assess the effect 
of age and gender on the association between BSA and mortality. 
 
Survival curves were plotted by the Kaplan–Meier method using the log‐rank test for assessing the 
significance of the differences in survival between BSA subgroups. As BSA values are commonly lower 
in females than in males, additional plots were made according to the specific quartiles of each gender. 
The results were considered statistically significant when the P‐value was <0.05. Analyses were 
performed with SAS statistical software version 9.4 (SAS Institute, Inc., Cary, NC, USA).  
Results 
Included in the study were 9104 participants of the outpatient cohort of the ESC Heart Failure Long‐
Term Registry. The baseline characteristics of the patients included in the study are presented in Table 1. 
Mean age of the study population was 64.8 ± 13.4 years, and there was predominance of men (71.6%). 
Only 25.7% were in NYHA functional class III–IV. An LVEF of ≤45% was documented in 77.0% of the 
patients. Ischaemic heart disease as a primary aetiology was present in 42.8% and diabetes mellitus in 
31.3%.  
  
Table 1. Baseline characteristics of patients according to body surface area (m2) 
 
All (n = 9104)  <1.78 (n = 2226)  1.78–2.07 (n = 4652)  >2.07 (n = 2226)  P‐value  
      
Age (years) 64.8 ± 13.4 67.6 ± 15.1 65.4 ± 12.8 60.6 ± 11.6 <0.001 
Female gender 2584/9104 (28.4%) 1310/2226 (58.9%) 1074/4652 (23.1%) 200/2226 (9.0%) <0.001 
BMI (kg/m2)  28.1 ± 5.1 23.8 ± 3.3 27.8 ± 3.6 33.0 ± 5.1 <0.001 
SBP (mmHg) 124.4 ± 21.0 120.8 ± 21.0 124.4 ± 20.7 128.1 ± 20.8 <0.001 
HR (b.p.m.) 73.2 ± 15.7 72.6 ± 15.3 72.6 ± 15.4 74.9 ± 16.5 <0.001 
EF (%) 37.1 ± 13.6 38.2 ± 15.1 37.0 ± 13.4 36.1 ± 12.5 0.008 
EF (%) median (IQR) 35 (27–45) 35 (27–49) 35 (28–45) 35 (27–45)  
NYHA III–IV 2343/9102 (25.7%) 599/2226 (26.9%) 1142/4651 (24.6%) 602/2225 (27.1%) 0.030 
Sound 3 547/9060 (6.0%) 126/2216 (5.7%) 281/4633 (6.1%) 140/2211 (6.3%) 0.661 
Mitral regurgitation 2415/9079 (26.6%) 619/2220 (27.9%) 1233/4640 (26.6%) 563/2219 (25.4%) 0.166 
Aortic stenosis 370/9077 (4.1%) 123/2219 (5.5%) 181/4640 (3.9%) 66/2218 (3.0%) <0.001 
HF history with previous hospitalization 3767/9043 (41.7%) 954/2219 (43.0%) 1904/4611 (41.3%) 909/2213 (41.1%) 0.335 
Ischaemic heart disease 3900/9104 (42.8%) 803/2226 (36.1%) 2139/4652 (46.0%) 958/2226 (43.0%) <0.001 
Atrial fibrillation 3370/9104 (37.0%) 780/2226 (35.0%) 1709/4652 (36.7%) 881/2226 (39.6%) 0.006 
Diabetes mellitus 2853/9104 (31.3%) 511/2226 (23.0%) 1486/4652 (31.9%) 856/2226 (38.5%) <0.001 
PAD 1100/9081 (12.1%) 273/2219 (12.3%) 583/4640 (12.6%) 244/2222 (11.0%) 0.162 
Hypertension 5357/9098 (58.9%) 1138/2223 (51.2%) 2756/4649 (59.3%) 1463/2226 (65.7%) <0.001 
COPD 1272/9089 (14.0%) 295/2222 (13.3%) 632/4643 (13.6%) 345/2224 (15.5%) 0.056 
Prior stroke/TIA 844/9098 (9.3%) 193/2224 (8.7%) 479/4648 (10.3%) 172/2226 (7.7%) 0.001 
Renal dysfunction 1746/9095 (19.2%) 453/2225 (20.4%) 905/4645 (19.5%) 388/2225 (17.4%) 0.036 
Hepatic dysfunction 320/9090 (3.5%) 70/2222 (3.2%) 167/4643 (3.6%) 83/2225 (3.7%) 0.531 
Depression 666/9075 (7.3%) 202/2215 (9.1%) 348/4637 (7.5%) 116/2223 (5.2%) <0.001 
CRT implantation 1187/9020 (13.2%) 285/2214 (12.9%) 611/4606 (13.3%) 291/2200 (13.2%) 0.899 
ICD implantation 2204/9028 (24.4%) 454/2216 (20.5%) 1165/4610 (25.3%) 585/2202 (26.6%) <0.001 
      
 
BMI, body mass index; BSA, body surface area; HF, heart failure; HR, heart rate; ICD, implantable cardioverter defibrillator; IQR, 
interquartile range; PAD, peripheral artery disease; SBP, systolic blood pressure; TIA, transient ischaemic attack. 
Study patients were divided according to quartiles of BSA [<1.78 m
2
 (Q1); (1.78–2.07 m2) (Q1–Q3); 
>2.07 m
2
 (Q3)]. Higher BSA subgroups were significantly associated with younger age and 
predominance of male gender. In addition, higher BSA was associated with greater prevalence of co‐
morbidities, including obesity, hypertension, diabetes mellitus, and AF. The rate of depression was 
inversely related to BSA.  
 
Drug treatment and laboratory blood tests during outpatient visits according to BSA subgroups are 
presented in Table 2. Almost 90% of patients were treated with ACE inhibitors or ARBs as well as beta‐
blockers; 83.1% with oral diuretics; and 59.5% with mineralocorticoid receptor antagonists (MRAs). The 
usage of these therapies was higher across BSA subgroups. Creatinine, uric acid, white blood cells, and 
high‐sensitivity C‐reactive protein levels were significantly higher with the increase in BSA levels (Table 
2).  
  
Table 2. Drug treatment and laboratory blood tests during outpatient visits according to body surface area (m2) 
 
All (n = 9104)  <1.78 (n = 2226)  1.78–2.07 (n = 4652)  >2.07 (n = 2226)  P‐value  
 
Drug treatment 
ACE inibitors/ARBs 8061/9093 (88.7%) 1836/2224 (82.6%) 4141/4644 (89.2%) 2084/2225 (93.7%) <0.001 
Beta‐blockers 8057/9101 (88.5%) 1885/2225 (84.7%) 4125/4650 (88.7%) 2047/2226 (92.0%) <0.001 
MRAs 5414/9101 (59.5%) 1270/2225 (57.1%) 2766/4650 (59.5%) 1378/2226 (61.9%) 0.005 
Diuretics, oral 7559/9100 (83.1%) 1823/2224 (82.0%) 3855/4650 (82.9%) 1881/2226 (84.5%) 0.072 
Digitalis 2106/9098 (23.2%) 511/2225 (23.0%) 1061/4647 (22.8%) 534/2226 (24.0%) 0.552 
Statins 5519/9100 (60.7%) 1188/2225 (53.4%) 2931/4649 (63.1%) 1400/2226 (62.9%) <0.001 
Antiplatelets 4480/9100 (49.2%) 1003/2225 (45.1%) 2403/4649 (51.7%) 1074/2226 (48.3%) <0.001 
Oral anticoagulant 3844/9099 (42.3%) 892/2225 (40.1%) 1951/4648 (42.0%) 1001/2226 (45.0%) 0.004 
Amiodarone 1276/9099 (14.0%) 275/2225 (12.4%) 644/4648 (13.9%) 357/2226 (16.0%) 0.002 
Ivabradine 763/9099 (8.4%) 203/2225 (9.1%) 370/4648 (8.0%) 190/2226 (8.5%) 0.255 
Nitrates 1763/9098 (19.4%) 400/2224 (18.0%) 954/4648 (20.5%) 409/2226 (18.4%) 0.017 
Calcium channel blockers 1039/9098 (11.4%) 191/2225 (8.6%) 549/4648 (11.8%) 299/2225 (13.4%) <0.001 
Laboratory blood tests 
WBC (cells/µL) 7613.6 ± 6098.4 7581.6 ± 10360.2 7539.7 ± 4312.0 7799.5 ± 2152.5 <0.001 
Creatinine (mg/dL) 1.29 ± 2.30 1.23 ± 0.92 1.28 ± 1.91 1.36 ± 3.63 <0.001 
Uric acid (mg/dL) 6.86 ± 2.79 6.46 ± 3.04 6.90 ± 2.90 7.17 ± 2.19 <0.001 
Total cholesterol (mg/dL) 167.94 ± 45.1 172.12 ± 45.82 166.40 ± 44.23 167.10 ± 45.93 <0.001 
Sodium (mmol/L) 139.37 ± 3.76 139.17 ± 3.91 139.44 ± 3.72 139.45 ± 3.66 0.131 
Potassium (mmol/L) 4.46 ± 0.53 4.47 ± 0.55 4.47 ± 0.52 4.42 ± 0.52 0.004 
hsCRP (mg/L) 7.14 ± 12.74 6.28 ± 11.12 6.66 ± 12.20 8.84 ± 14.87 <0.001 
Bilirubin (mg/dL) 0.87 ± 0.84 0.85 ± 0.64 0.86 ± 1.01 0.90 ± 0.59 0.027 
      
 
BSA, body surface area; hsCRP, high‐sensitivity C‐reactive protein; MRA, mineralocorticoid receptor antagonist; WBC, white 
blood cells. 
Follow‐up outcomes 
Data regarding mortality during 1‐year follow‐up were available in 8875 patients (97.5% of the study 
cohort). Out of this population, 718 (8.1%) patients have died. An inverse relationship between all‐cause 
mortality and BSA subgroups was observed: highest in the low BSA quartile (11.4%), lower mortality in 
the Q1–Q3 quartiles (7.6%), and lowest in the uppermost BSA quartile (5.7%), P < 0.001 (Table 3). 
Cardiovascular death was determined in 371 patients (4.2% of the study cohort) and was inversely 
associated with BSA subgroup distribution (P < 0.001). Recurrent HF hospitalizations during 1‐year 
follow‐up were documented in 1029 of 8316 patients (12.4%), and were not significantly different 
between BSA subgroups (P = 0.392). 
 
Table 3. One‐year outcomes according to body surface area subtypes (m2) 
 
All (n = 9104)  <1.78 (n = 2226)  1.78–2.07 (n = 4652)  >2.07 (n = 2226)  P‐value  
      
All causes of death 718/8875 (8.1%) 247/2165 (11.4%) 347/4541 (7.6%) 124/2169 (5.7%) <0.001 
CV death 371/8875 (4.2%) 131/2165 (6.1%) 178/4541 (3.9%) 62/2169 (2.8%) <0.001 
Non‐CV death 162/8875 (1.8%) 59/2165 (2.7%) 75/4541 (1.6%) 28/2169 (1.3%) <0.001 
Unknown 185/8875 (2.1%) 57/2165 (2.6%) 94/4541 (2.1%) 34/2169 (1.6%) 0.049 
HF hospitalization 1029/8316 (12.4%) 263/2049 (12.8%) 506/4255 (11.9%) 260/2012 (12.9%) 0.392 
      
 
BSA, body surface area; CV, cardiovascular; HF, heart failure. 
Predictors of all‐cause mortality 
Multivariable analysis was performed by Cox regression analysis to identify independent predictors 
for all causes of 1‐year mortality. Multiple variables including baseline characteristics, co‐morbidities, 
and drug therapies were significantly and independently associated with mortality, as shown in Table 4. 
Other than severely reduced functional class (NYHA III–IV) (HR 2.152, 95% CI 1.822–2.541), the 
lowest BSA quartile (BSA <1.78 m
2
) was the strongest predictor of 1‐year mortality compared with the 
highest quartile (BSA >2.07 m
2
) in the multivariate model (HR 1.823, 95% CI 1.398–2.376).  
Table 4. Multivariable predictors for all causes of 1‐year mortality 
Variable Multivariable analysis 
 
HR (95% CI) P‐value  
   
BSA < Q1a  1.823 (1.398–2.376) <0.0001 
BSA Q1–Q3a  1.255 (1.000–1.576) 0.0503 
Female genderb  0.657 (0.534–0.808) <0.0001 
Age (years) 1.026 (1.018–1.034) <0.0001 
Systolic BP (mmHg) 0.985 (0.981–0.989) <0.0001 
LVEF <45%c  1.387 (1.108–1.736) 0.0042 
NYHA III–IV 2.152 (1.822–2.541) <0.0001 
S3 gallop 1.374 (1.042–1.813) 0.0245 
Mitral regurgitation 1.223 (1.033–1.448) 0.0193 
Aortic stenosis 1.531 (1.140–2.055) 0.0047 
Atrial fibrillation 1.332 (1.129–1.572) 0.0007 
Diabetes mellitus 1.403 (1.188–1.657) <0.0001 
Peripheral vascular disease 1.463 (1.197–1.789) 0.0002 
Chronic kidney dysfunction 1.628 (1.366–1.940) <0.0001 
Hepatic dysfunction 1.342 (0.983–1.831) 0.0642 
Depression 1.411 (1.104–1.804) 0.0059 
ACE inhibitor and/or ARB 0.756 (0.615–0.929) 0.0079 
Beta‐blockers 0.653 (0.527–0.810) 0.0001 
   
 
BP, blood pressure; BSA, body surface area; CI, confidence interval; HR, 
hazard ratio; Q, quartile. 
a Reference value BSA > Q3.  
b Reference value male.  
c Reference value LVEF ≥45%
Table 5 shows the HR for 1‐year mortality according to BSA levels. In addition to the unadjusted 
model, data are presented after full adjustment for all significant covariates, and separately after 
adjustment for age and gender, the most significant parameters influencing BSA. BSA displayed a 
significant, stepwise, inverse relationship with all‐cause mortality in all models, including after 
comprehensive adjustment for confounders. The HR for 1‐year mortality was 1.823 (95% CI 1.398–
2.376) for the lowest quartile of BSA <1.78 m
2
 and 1.255 (95% CI 1.000–1.576) for the Q1–Q3 quartiles 
(1.78 < BSA <2.07 m
2
), compared with the highest quartile (BSA >2.07 m
2
). Moreover, entering BSA as 
a continuous variable showed similar results, with an adjusted HR of 0.908 (95% CI 0.870–0.948) for 
each increase of 0.1 m
2
 in BSA levels (Table 5). 
Table 5. Hazard ratios for 1‐year mortality according to body surface area 
Comparison Unadjusted HR (95% CI) 
HR adjusted for age and gender (95% 
CI) 
HR adjusted for alla (95% CI)  
    
BSA < Q1 vs. Q1–Q3 1.529 (1.299–1.800), P < 
0.001  
1.710 (1.438–2.033), P < 0.001  1.452 (1.197–1.760), P < 
0.001  
BSA < Q1 vs. >Q3 2.073 (1.670–2.572), P < 
0.001  
2.156 (1.709–2.721), P < 0.001  1.823 (1.398–2.376), P < 
0.001  
BSA Q1–Q3 vs. >Q3 1.355 (1.104–1.664), P = 
0.004  
1.261 (1.024–1.553), P = 0.029  1.255 (1.000–1.576), P = 
0.050  
BSA continuous (unit = 
0.1) 
0.888 (0.859–0.918), P < 
0.001  
0.871 (0.838–0.905), P < 0.001  0.908 (0.870–0.948), P < 
0.001  
    
 
Comparison between BSA quartiles or as a continuous variable, for each increase of 0.1 m2.  
BSA, body surface area; CI, confidence interval; HR, hazard ratio; Q, quartile. 
a See Table 4.  
The lowest BSA quartile was significantly associated with 1‐year mortality in both patients with 
preserved (≥45%) and reduced (<45%) LVEF (adjusted HR 2.048, 95% CI 1.045–4.013, P = 0.03, and 
1.804, 95% CI 1.351–2.408, P < 0.001 compared with the highest BSA quartile, respectively).  
 
Kaplan–Meier survival curves for all causes of death, stratified by BSA subgroups, are presented in 
Figure 1, showing the continuation of the graded inverse relationship between BSA subgroups and 
mortality also beyond the first year of follow‐up (log‐rank P < 0.0001). Because BSA is inherently 
influenced by gender, we additionally performed separate survival analysis according to BSA quartiles of 
each gender (Figure 2). In both genders, subjects with the lowest BSA quartile (males <1.84 m
2
 and 
females <1.64 m
2
) had significantly higher mortality rates (log‐rank P < 0.0001 for both genders). 
However, the stepwise association with mortality was more distinct in males.  
  
 
 
 
Figure 1. Kaplan–Meier curves for all causes of death by body surface area (BSA) subtypes. FU, follow‐up. 
  
 
 
 
Figure 2. Kaplan–Meier curves for all causes of death by body surface area (BSA) subtypes, separately for (A) males and (B) 
females. FU, follow‐up.  
 
  
Discussion 
The results of the present study indicate that BSA, a common measure of body size used for indexing 
physiological parameters, is inversely and progressively associated with all‐cause and cardiuovascular 
mortality, but not HF hospitalizations, in a large cohort of chronic HF patients. This relationship, 
coinciding with the ‘obesity paradox’, was noted even after significant adjustment for confounders, 
including age and gender. 
 
The phenomenon of the obesity paradox was repeatedly demonstrated in studies analysing cohorts of 
both acute and chronic HF patients.
2-8, 25
 This was documented even though obesity is a well‐established 
risk factor for HF.
1 
The main mechanism proposed for the obesity paradox in HF is the greater metabolic 
reserve existing in obese HF patients, in contrast to the catabolic and inflammatory changes leading to 
cardiac cachexia.
26 
However, other contributing factors were suggested, including lower sympathetic 
activation and earlier presentation of symptoms in the obese HF patients, and confounding factors such as 
age and gender, which may bias the results.
14-18, 27
 
 
The majority of studies analysing adiposity in HF identified obesity by measuring BMI. However, the 
accuracy and reliability of this method in defining obesity and correcting weight for height was 
questioned.
13, 20
 BSA correlates more closely to physiological parameters than body weight. Different 
formulae that estimate whole BSA were developed over the years.
24, 28
 The DuBois brothers were the first 
researchers (in 1915) to develop an equation incorporating both mass and height, based on data from nine 
cadavers.
29
 Years later, Mosteller suggested a simplified approximation to this formula in a letter 
published in 1987 in the New England Journal of Medicine.
23
 This simplified equation [BSA = (weight 
(kg) × height (cm)/3600)
1/2
] has been widely adopted over the years due to its ease of calculation.
28
 
Verbraecken and colleagues found a close agreement between Mosteller's equation and BSA values 
obtained with traditional complex methods, recommending that this formula deserves to be used as the 
first choice for BSA calculation in clinical research and practice.
24
 Importantly, they demonstrated the 
accuracy and applicability of the Mosteller equation not only in normal weight, but also in overweight 
and obese adults.  
 
Although BSA is commonly used in medicine as a biometric unit to adjust size, mass, and volume, its 
clinical significance as an outcome predictor in cardiovascular diseases was scantily investigated. A small 
BSA was found to be an independent negative outcome predictor after coronary artery bypass surgery.
30
 
An additional study found that adult candidates for heart transplantation with lower BSA, including most 
female patients, had worse prognosis.
31
 Moreover, specifically in chronic HF, Futter and colleagues found 
in a cohort of 2271 patients that BSA was a stronger predictor of mortality than other measures of body 
habitus including BMI, concluding that the greater the overall bulk of the body the better the survival.
20
 
The current study results are in concordance with these observations, demonstrating an inverse 
relationship between BSA and mortality in chronic HF patients, establishing low BSA as one of the 
strongest independent predictors of 1‐year mortality. The inverse relationship with mortality was 
stepwise, with a borderline prognostic significance of the middle vs. high BSA subgroup in the 
multivariate analysis.  
 
The lack of association between BSA and HF hospitalization rates observed in the current study was 
similarly shown in a recent meta‐analysis investigating the relationship of BMI and outcomes in patients 
with chronic HF.
8 
In both studies, a U‐shaped association with rehospitalizations was demonstrated, 
which was distinct from the inverse relationship which was seen with mortality.  
 
In contrast to BMI, there are consistently and significantly higher BSA values in males than in 
females, both in normal weight and in overweight and obese subjects. The commonly accepted 50th 
percentiles for BSA are 1.94 m
2
 for adult men and 1.69 m
2
 for adult women.
24
 As expected, this 
observation was also noted in the present study, in which the gender distribution varied significantly 
across BSA quartiles. Therefore, we have adjusted the HRs of mortality for age and gender in a separate 
model, and analysed survival curves according to the BSA quartiles of each gender individually. The 
obesity paradox was demonstrated in both genders; however, there was a stronger inverse association 
between BSA and mortality in males compared with females. This finding could be partly due to the 
significantly higher mortality rates observed in males than in females in our HF cohort.  
Limitations 
The current study is based on an observational multicentre registry of HF patients. Some important 
limitations of this registry are acknowledged elsewhere.
22
 Additional co‐morbidities and cardiovascular 
risk factors influencing HF progression and outcomes may not have been evaluated in the ESC HF 
registry and therefore may account for residual confounding effects which were not adjusted for in the 
present study. Moreover, we have not used statistical methods such as propensity score analysis for 
matching imbalances in baseline characteristics and disease severity between BSA subgroups. ç 
 
Body surface ares was estimated based on a commonly used formula and not on actual BSA 
measurements using methods such as three‐dimensional whole‐body scanning. In addition, several studies 
have pointed out that BSA calculation is less accurate in severely obese subjects, which may have 
influenced the results. Moreover, we have not compared the predictive ability of BSA with BMI, the more 
commonly investigated parameter in studies analysing the obesity paradox in HF, nor have we evaluated 
whether BSA is linked to differences in body fat distribution. These important questions should be 
addressed in future studies. 
Conclusions 
Body surface area is a strong independent predictor of mortality in chronic HF subjects. Similar to 
other measures of body habitus, the obesity paradox is observed in HF using Mosteller's formula for BSA 
estimation. Since BSA is routinely calculated for indexing physiological parameters in the cardiovascular 
field, it may serve as an important and practicable prognostic indicator for adverse outcomes in chronic 
HF patients. 
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